<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00430924</url>
  </required_header>
  <id_info>
    <org_study_id>B109LB1</org_study_id>
    <secondary_id>2006-004411-21</secondary_id>
    <nct_id>NCT00430924</nct_id>
  </id_info>
  <brief_title>Inhibition of Aldosterone in Patients With Chronic Renal Disease</brief_title>
  <official_title>The Effect of Aldosterone Inhibition on Proteinuria in Patients With Progressive Renal Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lene Boesby</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Herlev Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine whether the inhibition of aldosterone will result in
      lower excretion of protein via urine. The hypothesis is that if loss of protein is lowered,
      progression of renal disease with be slower than otherwise expected.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with chronic renal disease are likely to progress to end stage renal disease with
      the need for renal replacement therapy. It is accepted that proteinuria is a surrogate
      measurement for progression. If proteinuria can be lowered we hope to prolong patients
      pre-dialysis phase. Our theory is that aldosterone inhibition will lead to this.

      For a period of 8 weeks patients will be randomized to either aldosterone receptor inhibition
      with the drug eplerenone or control without. Blood pressures will be kept at the same level
      using other drugs.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proteinuria reduction</measure>
    <time_frame>bi-monthly</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluating blood pressure response and hyperkalaemia after aldosterone inhibition.</measure>
    <time_frame>weekly</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Kidney Failure, Chronic</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eplerenone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eplerenone</intervention_name>
    <description>Once daily administration for 8 weeks and 8 weeks control.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Proteinuria &gt; 500 mg/24 hours

          -  Hypertension or anti-hypertensive treatment

        Exclusion Criteria:

          -  Diabetic nephropathy

          -  GFR&lt; 20 ml/min

          -  P-potassium between 3,5 mmol/l and 5,0 mmol/l
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Svend Strandgaard, DMSc</last_name>
    <role>Study Director</role>
  </overall_official>
  <overall_official>
    <last_name>Anne-Lise Kamper, DMSc</last_name>
    <role>Study Director</role>
    <affiliation>nonaffiliated</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rigshospitalet, Blegdamsvej 9</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2100 Ã˜</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>DK-2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <link>
    <url>http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0026904</url>
    <description>Publication</description>
  </link>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2007</study_first_submitted>
  <study_first_submitted_qc>February 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2007</study_first_posted>
  <last_update_submitted>February 7, 2012</last_update_submitted>
  <last_update_submitted_qc>February 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Herlev Hospital</investigator_affiliation>
    <investigator_full_name>Lene Boesby</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Kidney Failure, Chronic</keyword>
  <keyword>Proteinuria</keyword>
  <keyword>Aldosterone</keyword>
  <keyword>Renin-Angiotensin System</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eplerenone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

